Literature DB >> 24986687

Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.

Cassandra J Vandenberg1, Paul Waring2, Andreas Strasser1, Suzanne Cory1.   

Abstract

Mice susceptible to plasma cell tumors provide a useful model for human multiple myeloma. We previously showed that mice expressing an Eµ-v-abl oncogene solely develop plasmacytomas. Here we show that loss of the proapoptotic BH3-only protein Bim or, to a lesser extent, overexpression of antiapoptotic Bcl-2 or Mcl-1, significantly accelerated the development of plasmacytomas and increased their incidence. Disease was preceded by an increased abundance of plasma cells, presumably reflecting their enhanced survival capacity in vivo. Plasmacytomas of each genotype expressed high levels of v-abl and frequently harbored a rearranged c-myc gene, probably as a result of chromosome translocation. As in human multiple myelomas, elevated expression of cyclin D genes was common, and p53 deregulation was rare. Our results for plasmacytomas highlight the significance of antiapoptotic changes in multiple myeloma, which include elevated expression of Mcl-1 and, less frequently, Bcl-2, and suggest that closer attention to defects in Bim expression is warranted.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24986687      PMCID: PMC4133484          DOI: 10.1182/blood-2014-04-570770

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  78 in total

1.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.

Authors:  P Bouillet; D Metcalf; D C Huang; D M Tarlinton; T W Kay; F Köntgen; J M Adams; A Strasser
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

2.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.

Authors:  C Bouchard; O Dittrich; A Kiermaier; K Dohmann; A Menkel; M Eilers; B Lüscher
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

Review 3.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

Review 4.  Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases.

Authors:  Andreas Strasser; Suzanne Cory; Jerry M Adams
Journal:  EMBO J       Date:  2011-08-23       Impact factor: 11.598

5.  Inhibition of v-Abl transformation by p53 and p19ARF.

Authors:  F Cong; X Zou; K Hinrichs; K Calame; S P Goff
Journal:  Oncogene       Date:  1999-12-16       Impact factor: 9.867

Review 6.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

7.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

8.  Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.

Authors:  Kirsteen J Campbell; Mary L Bath; Marian L Turner; Cassandra J Vandenberg; Philippe Bouillet; Donald Metcalf; Clare L Scott; Suzanne Cory
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

9.  NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression.

Authors:  Yukio Nakamura; Raelene J Grumont; Steve Gerondakis
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Signaling by ABL oncogenes through cyclin D1.

Authors:  D E Afar; J McLaughlin; C J Sherr; O N Witte; M F Roussel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

View more
  6 in total

1.  The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.

Authors:  Kerstin Brinkmann; Stephanie Grabow; Craig D Hyland; Charis E Teh; Warren S Alexander; Marco J Herold; Andreas Strasser
Journal:  Cell Death Differ       Date:  2017-08-11       Impact factor: 15.828

Review 2.  Viewing BCL2 and cell death control from an evolutionary perspective.

Authors:  Andreas Strasser; David L Vaux
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

3.  PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.

Authors:  A A Guirguis; C I Slape; L M Failla; J Saw; C S Tremblay; D R Powell; F Rossello; A Wei; A Strasser; D J Curtis
Journal:  Cell Death Differ       Date:  2016-01-08       Impact factor: 15.828

Review 4.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

Review 5.  Mouse models of multiple myeloma: technologic platforms and perspectives.

Authors:  Marco Rossi; Cirino Botta; Mariamena Arbitrio; Rosa Daniela Grembiale; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2018-04-13

Review 6.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.